Edition:
United States

Atossa Genetics Inc (ATOS.OQ)

ATOS.OQ on NASDAQ Stock Exchange Capital Market

0.33USD
3:59pm EST
Change (% chg)

$0.02 (+8.13%)
Prev Close
$0.31
Open
$0.30
Day's High
$0.34
Day's Low
$0.28
Volume
333,106
Avg. Vol
598,834
52-wk High
$1.85
52-wk Low
$0.28

Latest Key Developments (Source: Significant Developments)

Atossa Genetics posts Q3 loss per share ‍$0.18​
Tuesday, 14 Nov 2017 08:00am EST 

Nov 14 (Reuters) - Atossa Genetics Inc :Atossa Genetics announces third quarter 2017 financial results and provides company update.Atossa Genetics Inc qtrly loss per share ‍$0.18​.  Full Article

L1 Capital Global Opportunities Master Fund reports 9.01 pct passive stake in ‍atossa Genetics, as of Oct. 26
Friday, 3 Nov 2017 05:25pm EDT 

Nov 3 (Reuters) - L1 Capital Global Opportunities Master Fund Ltd: :L1 capital global opportunities master fund ltd reports 9.01% passive stake in ‍atossa genetics inc, as of october 26, 2017 - SEC filing‍​.  Full Article

Empery Asset Management reports 9.01 pct passive stake in Atossa Genetics
Tuesday, 31 Oct 2017 03:02pm EDT 

Oct 31 (Reuters) - Empery Asset Management LP::Empery Asset Management LP reports 9.01 percent passive stake in Atossa Genetics as of Oct 26 - SEC filing‍​.  Full Article

Atossa Genetics announces pricing of $5.1 million public offering
Thursday, 26 Oct 2017 09:00am EDT 

Oct 26 (Reuters) - Atossa Genetics Inc :Atossa Genetics announces pricing of $5.1 million public offering of common stock.Says public offering of 11.5 million common shares priced at $0.44per share.  Full Article

Atossa Genetics announces proposed public offering of common stock
Wednesday, 25 Oct 2017 06:25pm EDT 

Oct 25 (Reuters) - Atossa Genetics Inc ::Atossa Genetics announces proposed public offering of common stock.Says ‍intends to offer and sell shares of its common stock in an underwritten public offering​.  Full Article

Atossa Genetics announces upcoming Phase 2 study of topical Endoxifen
Monday, 25 Sep 2017 08:00am EDT 

Sept 25 (Reuters) - Atossa Genetics Inc :Atossa Genetics announces upcoming Phase 2 study of topical Endoxifen.Atossa Genetics - ‍ Atossa plans to apply for approval from Institutional Review Board and Swedish regulatory authority within next 30 days​.  Full Article

Atossa Genetics files for mixed shelf of upto $50 million
Friday, 22 Sep 2017 04:46pm EDT 

Sept 23 (Reuters) - Atossa Genetics Inc :Atossa Genetics Inc files for mixed shelf of upto $50 million - SEC filing.‍​.  Full Article

Atossa Genetics reports Q2 ‍loss per share $0.64​
Monday, 14 Aug 2017 04:30pm EDT 

Aug 14 (Reuters) - Atossa Genetics Inc -:Atossa Genetics announces second quarter 2017 financial results and provides company update.Atossa Genetics Inc qtrly ‍loss per share $0.64​.  Full Article

Atossa Genetics says on June 29, offered to modify rights of holders of warrants issued in public offering company completed on April 3 - SEC Filing
Friday, 30 Jun 2017 09:35am EDT 

June 30 (Reuters) - Atossa Genetics Inc :Atossa Genetics - On June 29, offered to modify rights of holders of warrants issued in public offering company completed on April 3, 2017 - SEC Filing.Atossa Genetics Inc - Temporary modification includes lowering exercise price of warrants to $0.26 per share.Atossa Genetics Inc - Temporary modification includes setting applicable VWAP price at $0.52 per share.Atossa Genetics Inc - In connection with temporary modification, agreed to extend lock-up period in underwriting agreement.  Full Article

Atossa Genetics qtrly loss per basic common share $0.45
Thursday, 11 May 2017 05:31pm EDT 

May 11 (Reuters) - Atossa Genetics Inc ::Qtrly loss per basic common share $0.45."we are in the research and development phase and do not generate revenue".Plans to commence a phase 2 clinical study of endoxifen in second half of 2017.  Full Article

BRIEF-Atossa Genetics posts Q3 loss per share ‍$0.18​

* Atossa Genetics announces third quarter 2017 financial results and provides company update